Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-101684362 (HLD-0117) in ER+ Metastatic Breast Cancer
NCT07524855Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of JNJ-101684362 in breast cancer, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events, ECGs, Labs and Clinical Changes at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
JNJ-101684362
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07524855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524855.